Advice for Community Oncologists who Treat Patients with NSCLC

The FDA has given the novel agent NVL-655 a breakthrough therapy designation for the treatment of patients with ALK-positive locally advanced or metastatic non-small cell lung cancer.

In this episode of Targeted Talks, Aaron Lisberg, MD, discusses results from the phase 3 TROPION-Lung01 study of datopotamab in advanced or metastatic non–small cell lung cancer.

A pivotal phase 2 study evaluating glecirasib for the treatment of KRAS G12C-mutated advanced non-small cell lung cancer met its primary end point with an encouraging overall response rate.

In season 4, episode 13 of Targeted Talks, Benny Weskler, MBA, MD, FACS, FACCP, discusses neoadjuvant therapy for patients with non–small cell lung cancer.

Following its recent FDA approval in non-muscle-invasive bladder cancer, nogapendekin alfa has also shown overall survival benefits in addition to checkpoint inhibitor therapy in patients with non-small cell lung cancer.

During a Case-Based Roundtable® event, Misako Nagasaka, MD, discussed treatment for a patient with non–small cell lung cancer and an EGFR exon 20 insertion.